159 related articles for article (PubMed ID: 28621538)
1. Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
Lorthiois E; Anderson K; Vulpetti A; Rogel O; Cumin F; Ostermann N; Steinbacher S; Mac Sweeney A; Delgado O; Liao SM; Randl S; Rüdisser S; Dussauge S; Fettis K; Kieffer L; de Erkenez A; Yang L; Hartwieg C; Argikar UA; La Bonte LR; Newton R; Kansara V; Flohr S; Hommel U; Jaffee B; Maibaum J
J Med Chem; 2017 Jul; 60(13):5717-5735. PubMed ID: 28621538
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.
Karki RG; Powers J; Mainolfi N; Anderson K; Belanger DB; Liu D; Ji N; Jendza K; Gelin CF; Mac Sweeney A; Solovay C; Delgado O; Crowley M; Liao SM; Argikar UA; Flohr S; La Bonte LR; Lorthiois EL; Vulpetti A; Brown A; Long D; Prentiss M; Gradoux N; de Erkenez A; Cumin F; Adams C; Jaffee B; Mogi M
J Med Chem; 2019 May; 62(9):4656-4668. PubMed ID: 30995036
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule factor D inhibitors targeting the alternative complement pathway.
Maibaum J; Liao SM; Vulpetti A; Ostermann N; Randl S; Rüdisser S; Lorthiois E; Erbel P; Kinzel B; Kolb FA; Barbieri S; Wagner J; Durand C; Fettis K; Dussauge S; Hughes N; Delgado O; Hommel U; Gould T; Mac Sweeney A; Gerhartz B; Cumin F; Flohr S; Schubart A; Jaffee B; Harrison R; Risitano AM; Eder J; Anderson K
Nat Chem Biol; 2016 Dec; 12(12):1105-1110. PubMed ID: 27775713
[TBL] [Abstract][Full Text] [Related]
5. Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration.
Loyet KM; Good J; Davancaze T; Sturgeon L; Wang X; Yang J; Le KN; Wong M; Hass PE; van Lookeren Campagne M; Haughney PC; Morimoto A; Damico-Beyer LA; DeForge LE
J Pharmacol Exp Ther; 2014 Dec; 351(3):527-37. PubMed ID: 25232192
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Schubart A; Anderson K; Mainolfi N; Sellner H; Ehara T; Adams CM; Mac Sweeney A; Liao SM; Crowley M; Littlewood-Evans A; Sarret S; Wieczorek G; Perrot L; Dubost V; Flandre T; Zhang Y; Smith RJH; Risitano AM; Karki RG; Zhang C; Valeur E; Sirockin F; Gerhartz B; Erbel P; Hughes N; Smith TM; Cumin F; Argikar UA; Haraldsson B; Mogi M; Sedrani R; Wiesmann C; Jaffee B; Maibaum J; Flohr S; Harrison R; Eder J
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7926-7931. PubMed ID: 30926668
[TBL] [Abstract][Full Text] [Related]
7. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
[TBL] [Abstract][Full Text] [Related]
8. Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.
Dobó J; Kocsis A; Gál P
Front Immunol; 2018; 9():1851. PubMed ID: 30135690
[TBL] [Abstract][Full Text] [Related]
9. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular weight inhibitors of the alternative complement pathway.
Schubart A; Flohr S; Junt T; Eder J
Immunol Rev; 2023 Jan; 313(1):339-357. PubMed ID: 36217774
[TBL] [Abstract][Full Text] [Related]
11. Age-related macular degeneration: a complementopathy?
Kijlstra A; Berendschot TT
Ophthalmic Res; 2015; 54(2):64-73. PubMed ID: 26159686
[TBL] [Abstract][Full Text] [Related]
12. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration.
Richards A; Kavanagh D; Atkinson JP
Adv Immunol; 2007; 96():141-77. PubMed ID: 17981206
[TBL] [Abstract][Full Text] [Related]
13. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification.
Harboe M; Garred P; Karlstrøm E; Lindstad JK; Stahl GL; Mollnes TE
Mol Immunol; 2009 Dec; 47(2-3):373-80. PubMed ID: 19800125
[TBL] [Abstract][Full Text] [Related]
14. Dengue virus and the complement alternative pathway.
Carr JM; Cabezas-Falcon S; Dubowsky JG; Hulme-Jones J; Gordon DL
FEBS Lett; 2020 Aug; 594(16):2543-2555. PubMed ID: 31943152
[TBL] [Abstract][Full Text] [Related]
15. Induction of Ocular Complement Activation by Inflammatory Stimuli and Intraocular Inhibition of Complement Factor D in Animal Models.
Crowley MA; Delgado O; Will-Orrego A; Buchanan NM; Anderson K; Jaffee BD; Dryja TP; Liao SM
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):940-951. PubMed ID: 29450541
[TBL] [Abstract][Full Text] [Related]
16. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition.
Yu J; Yuan X; Chen H; Chaturvedi S; Braunstein EM; Brodsky RA
Blood; 2020 Oct; 136(18):2080-2089. PubMed ID: 32877502
[TBL] [Abstract][Full Text] [Related]
17. Scaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors.
Zhang W; Wu M; Vadlakonda S; Juarez L; Cheng X; Muppa S; Chintareddy V; Vogeti L; Kellogg-Yelder D; Williams J; Polach K; Chen X; Raman K; Babu YS; Kotian P
Bioorg Med Chem; 2022 Nov; 74():117034. PubMed ID: 36272185
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-((2
Mainolfi N; Ehara T; Karki RG; Anderson K; Mac Sweeney A; Liao SM; Argikar UA; Jendza K; Zhang C; Powers J; Klosowski DW; Crowley M; Kawanami T; Ding J; April M; Forster C; Serrano-Wu M; Capparelli M; Ramqaj R; Solovay C; Cumin F; Smith TM; Ferrara L; Lee W; Long D; Prentiss M; De Erkenez A; Yang L; Liu F; Sellner H; Sirockin F; Valeur E; Erbel P; Ostermeier D; Ramage P; Gerhartz B; Schubart A; Flohr S; Gradoux N; Feifel R; Vogg B; Wiesmann C; Maibaum J; Eder J; Sedrani R; Harrison RA; Mogi M; Jaffee BD; Adams CM
J Med Chem; 2020 Jun; 63(11):5697-5722. PubMed ID: 32073845
[TBL] [Abstract][Full Text] [Related]
19. Lutein and Factor D: two intriguing players in the field of age-related macular degeneration.
Tian Y; Kijlstra A; Webers CAB; Berendschot TTJM
Arch Biochem Biophys; 2015 Apr; 572():49-53. PubMed ID: 25637656
[TBL] [Abstract][Full Text] [Related]
20. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
